Migard (Frovatriptan)

Frovatriptan, the active ingredient in Migard, is a selective serotonin 5‑HT1B/1D receptor agonist presented as a tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults, providing relief from headache and associated symptoms.

GNH USA supplies Migard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory documentation to support import and distribution across global markets. Clients benefit from reliable logistics, batch traceability, and responsive technical support throughout the supply chain.

Frovatriptan is used in the acute treatment of migraine and related headache disorders.

Migraine (with or without aura): provides rapid relief of headache pain, accompanying nausea, photophobia and phonophobia, typically within two hours of administration. Menstrual migraine: reduces the frequency and severity of attacks linked to the menstrual cycle, offering a convenient option for women with predictable hormonal triggers.

Frovatriptan may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Chest discomfort - Tingling or numbness - Dizziness - Nausea - Dry mouth - Fatigue

Serious or Rare Side Effects: - Coronary vasospasm - Severe hypertension - Serotonin syndrome - Allergic reactions (rash, swelling, anaphylaxis) - Cardiac arrhythmia - Ischemic events (stroke, myocardial infarction)

When prescribing frovatriptan, clinicians should observe several precautionary measures to minimise risk.

Assess cardiovascular risk: evaluate history of coronary artery disease, hypertension or cerebrovascular disorders before use. Avoid concomitant ergotamine: combined vasoconstrictive effects may precipitate severe vascular events. Monitor serotonin syndrome: do not co‑administer with other serotonergic agents such as SSRIs, SNRIs or MAO inhibitors. Use caution in older adults: patients over 65 may experience heightened sensitivity to side effects. Store at ambient temperature: keep tablets in the original packaging, protect from moisture and store below 25 °C.

Frovatriptan interacts with several medicines; understanding the level of interaction guides safe co‑administration.

Major Interactions (Avoid): - Ergotamine derivatives: additive vasoconstriction can cause serious cardiovascular events. - Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome when combined.

Moderate Interactions (Monitor Closely): - SSRIs and SNRIs: may elevate serotonin levels; monitor for signs of serotonin syndrome. - CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin): raise frovatriptan plasma concentrations, possibly enhancing side effects. - Antihypertensive agents: concurrent use may augment blood pressure‑lowering effects.